ScienceDaily (May 31, 2000) — COLUMBUS, Ohio - Smokers who are hopeful that hypnosis will help them kick their habit need to temper their expectations, according to new research.
A review of nearly five dozen studies showed that while hypnosis may have some effect as an anti-smoking treatment, it is by no means an end-all and be-all treatment for smoking cessation.
"Giving hypnosis the stamp of a well-established treatment for smoking cessation is premature," said Joseph Green, a study co-author and associate professor of psychology at Ohio State University's Lima campus.
Click here to read entire article at Science Daily.com
Wednesday, May 31, 2000
Friday, March 10, 2000
Anti-Cocaine Vaccine Produces Antibodies, Shown To Be Safe In Yale Researcher's Phase 1 Study
ScienceDaily (Mar. 10, 2000) — New Haven, Conn. -- A therapeutic cocaine vaccine designed to suppress the high addicts get from taking cocaine is safe and produced cocaine antibodies in humans, a Yale study finds.
Thomas Kosten, M.D., principal investigator on the phase 1 study, and his team administered the vaccine to 34 former cocaine abusers living in a residential treatment facility.
The vaccine, TA-CD, is designed to generate drug-specific antibodies, which bind to cocaine and prevent it from traveling to the brain from the bloodstream. This neutralizes its psychoactive effect.
"The vaccine is very safe and we did not observe any major side effects," said Kosten, professor of psychiatry at Yale School of Medicine. "TA-CD was effective in producing cocaine-specific antibodies, which lasted throughout the trial. More advanced trials are already underway. TA-CD offers the potential for a completely new and highly viable approach to a very serious problem for which there are no alternative therapies available.
Click here to read entire article at Science Daily.com
Thomas Kosten, M.D., principal investigator on the phase 1 study, and his team administered the vaccine to 34 former cocaine abusers living in a residential treatment facility.
The vaccine, TA-CD, is designed to generate drug-specific antibodies, which bind to cocaine and prevent it from traveling to the brain from the bloodstream. This neutralizes its psychoactive effect.
"The vaccine is very safe and we did not observe any major side effects," said Kosten, professor of psychiatry at Yale School of Medicine. "TA-CD was effective in producing cocaine-specific antibodies, which lasted throughout the trial. More advanced trials are already underway. TA-CD offers the potential for a completely new and highly viable approach to a very serious problem for which there are no alternative therapies available.
Click here to read entire article at Science Daily.com
Monday, August 17, 1998
Hopkins Study Shows Languishing Addictions Drug Really Works
ScienceDaily (Aug. 17, 1998) — A longer-acting alternative to methadone that never quite caught on following its FDA approval in 1993 may now greatly increase the number of addicts who stick with treatment, thanks to a new Johns Hopkins study.
The study suggests better ways of taking LAAM (levomethadyl acetate hydrochloride), a drug similar to methadone in its capacity to discourage heroin use and block withdrawal symptoms. However, unlike methadone, which addicts must use daily, LAAM can be taken three times a week, making it far more convenient and potentially less expensive.
LAAM isn't widely used, because of both uncertainties about how effective it is in the first stages of addiction treatment and doubts that it would be accepted by addicts. Earlier this year, for example, only about 3,000 U.S. patients were getting the drug.
Click here to read entire article at Science Daily.com
The study suggests better ways of taking LAAM (levomethadyl acetate hydrochloride), a drug similar to methadone in its capacity to discourage heroin use and block withdrawal symptoms. However, unlike methadone, which addicts must use daily, LAAM can be taken three times a week, making it far more convenient and potentially less expensive.
LAAM isn't widely used, because of both uncertainties about how effective it is in the first stages of addiction treatment and doubts that it would be accepted by addicts. Earlier this year, for example, only about 3,000 U.S. patients were getting the drug.
Click here to read entire article at Science Daily.com
Subscribe to:
Posts (Atom)